ALNY

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases.

Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 05, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sac...

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Alnylam Pharmaceuticals, Inc.'s ( NASDAQ:ALNY ) price-to-sales (or "P/S") ratio of 20.1x might make it look like a......

Alnylam (ALNY) Reports Positive Results From APOLLO-B Study

Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months....

Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., May 20, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from an interim analysis of exploratory data from the o...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2023 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2023 Earnings Call Transcript May 4, 2023 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.4, expectations were $-1.76. Ope...

Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.